Dermatomyositis and polymyositis (myositis): vizsgálatok itt: Egyesült Államok
34 of 45 trials · From ClinicalTrials.gov, checked 2026. november 19.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Where
- Atlanta, Baltimore, Bethesda, Birmingham, Boston, Chicago, City of Saint Peters, Columbus, Creve Coeur, Dallas, Detroit, Fairway, Fort Worth, Hays, Houston, Kansas City, Lawrence, Lee's Summit, Lexington, Mineola, New Brunswick, New Haven, New York, North Kansas City, Olathe, Overland Park, Palo Alto, Philadelphia, Pittsburg, Pittsburgh, Richardson, Richmond, Sacramento, Salina, Salt Lake City, St Louis, Topeka, Washington D.C., Westwood
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT03816345 - 2. fázisTaking peopleFAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
- Where
- Bethesda
- Életkor
- 18 év to 62 év
- People
- 3000
- Run by
- National Institute of Environmental Health Sciences (NIEHS)
See details and how to joinNCT07111065 - 2/3. fázisTaking peopleRESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Where
- Ann Arbor, Atlanta, Aurora, Bethesda, Boston, Chapel Hill, Chicago, Dallas, Durham, Houston, Jacksonville, Kansas City, Milwaukee, Nashville, New York, Orange, Philadelphia, Pittsburgh, Portland, Rochester, Salt Lake City, San Francisco, Seattle, St. Petersburg, The Bronx
- Életkor
- 6 év to 75 év
- People
- 74 worldwide
- Run by
- Cabaletta Bio
See details and how to joinNCT06154252 · EU 2025-521145-24-01 - 2. fázisTaking peopleUblituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- Where
- Atlanta, Baltimore, Birmingham, Chicago, Great Neck, Houston, Pittsburgh, Rochester
- Életkor
- 18 év and over
- People
- 30
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
See details and how to joinNCT07103746 - 3. fázisNot yet taking people in Egyesült ÁllamokA Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
- Where
- Ann Arbor, Aurora, Baltimore, Boston, Chicago, Cleveland, Dallas, Fairway, Great Neck, Hershey, Houston, Irvine, Jackson, Los Angeles, Middleburg Heights, Philadelphia, Pittsburgh, Portland, Rochester, San Francisco, Scottsdale, St Louis
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07789015 · EU 2026-526365-24-00 - 1/2. fázisTaking peopleA Study of AZD0120 in Autoimmune Diseases
- Where
- Ann Arbor, Baltimore, Chapel Hill, Chicago, Duarte, Miami, New York, Seattle, Stanford, St Louis, Tucson
- Életkor
- 18 év to 75 év
- People
- 27 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07295847 - 1. fázisTaking peopleA Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Where
- Aurora, Baltimore, Charleston, Charlotte, Chicago, Durham, East Brunswick, Greenville, Iowa City, Jacksonville, Kansas City, Loma Linda, Louisville, New York, Phoenix, Salt Lake City, Valhalla
- Életkor
- 18 év to 74 év
- People
- 66 worldwide
- Run by
- Allogene Therapeutics
See details and how to joinNCT07085104 - 1/2. fázisTaking peopleA Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Where
- Ann Arbor, Charlotte, Dallas, Fairway, Hackensack, Los Angeles, Minneapolis, New York, Plantation, Summit, Syracuse, Tampa
- Életkor
- 18 év to 75 év
- People
- 240
- Run by
- Nkarta, Inc.
See details and how to joinNCT06733935 - 2. fázisTaking peopleTopical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
- Where
- Cleveland
- Életkor
- 18 év to 89 év
- People
- 15
- Run by
- The Cleveland Clinic
See details and how to joinNCT06857240 - 1. fázisTaking peopleA Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Where
- Boston, Chapel Hill, Chicago, Iowa City, La Jolla, New Orleans, Portland, Redwood City, St Louis
- Életkor
- 18 év to 70 év
- People
- 80 worldwide
- Run by
- CRISPR Therapeutics
See details and how to joinNCT06925542 - 1. fázisTaking peopleA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Where
- Anniston, Birmingham, Chapel Hill, Iowa City, La Jolla, Omaha, Sacramento
- Életkor
- 18 év to 70 év
- People
- 72 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00 - 3. fázisCsak meghívásosA Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
- Where
- Atlanta, Austin, Baltimore, Beverly Hills, Chapel Hill, Chicago, Columbus, Gainesville, Great Neck, Houston, Jacksonville, New Haven, Orange, Phoenix, Pittsburgh, Portland, San Francisco, Tampa
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- argenx
See details and how to joinNCT05979441 · EU 2022-502851-79-00 - 1. fázisNot yet taking people in Egyesült ÁllamokA Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
- Where
- Ann Arbor, Great Neck, Morristown, Newport Beach, Omaha, Philadelphia, Saint Paul, Salt Lake City, Seattle, Worcester
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07873931 - 1. fázisCsak meghívásosA Study of KITE-363 in Participants With Refractory Autoimmune Diseases
- Where
- Duarte, New York, Stanford, Tampa
- Életkor
- 18 év and over
- People
- 52 worldwide
- Run by
- Kite, A Gilead Company
See details and how to joinNCT07038447 - 3. fázisTaking peopleA Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
- Where
- Allen, Amarillo, Ann Arbor, Atlanta, Aurora, Austin, Baltimore, Beckley, Boca Raton, Boston, Boynton Beach, Charleston, Charlotte, Cleveland, Colleyville, Denver, Durham, El Paso, Fairway, Gainesville, Galveston, Great Neck, Harlingen, Houston, Irvine, Margate, Miami, Middleburg Heights, Milwaukee, New Haven, North Richland Hills, Orlando, Palm Beach Gardens, Philadelphia, Phoenix, Pittsburgh, Plant City, Sterling Heights, Summerville, Washington D.C., Willowbrook
- Életkor
- 18 év to 75 év
- People
- 240 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06455449 - 3. fázisTaking peopleA Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- Where
- Beckley, Boston, Cleveland, Edinburg, Frisco, Glendale, Harlingen, Houston, Jacksonville, Katy, Los Angeles, Margate, Miami, New York, Oklahoma City, Orange, Orlando, Phoenix, Pittsburgh, Plantation, Rancho Mirage, Scottsdale, St Louis, Tamarac, Weslaco
- Életkor
- 18 év and over
- People
- 318 worldwide
- Run by
- Pfizer
See details and how to joinNCT05895786 · EU 2022-502739-20-00 - 1/2. fázisTaking peopleFT839 in Autoimmune Diseases
- Where
- Fullerton
- Életkor
- 18 év to 70 év
- People
- 446
- Run by
- Fate Therapeutics
See details and how to joinNCT07800871 - 3. fázisTaking peopleA Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- Where
- Beckley, Frisco, Glendale, Houston
- Életkor
- 18 év and over
- People
- 211 worldwide
- Run by
- Pfizer
See details and how to joinNCT06698796 · EU 2024-514648-10-00 - 2. fázisTaking peopleEmapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
- Where
- Miami
- Életkor
- 18 év and over
- People
- 5
- Run by
- University of Miami
See details and how to joinNCT07486869 - 2. fázisTaking peopleDescartes-08 in Autoantibody Myositis
- Where
- Austin, Boston, Chapel Hill, Orange
- Életkor
- 18 év and over
- People
- 60
- Run by
- Cartesian Therapeutics
See details and how to joinNCT07391605 - 2. fázisTaking peopleAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Where
- Arlington, Bellaire, Charleston, Charlotte, Chula Vista, Covina, Gainesville, Great Falls, Hixson, Iowa City, Irving, Jackson, Jupiter, Katy, Los Alamitos, Los Angeles, Mesquite, Miami, Norcross, Phoenix, Plantation, Red Oak, Roanoke, Santa Ana, Statesville, Tucson, Tuscaloosa, Tustin, Willowbrook, Woodland
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00 - 1. fázisNot yet taking people in Egyesült ÁllamokBAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
- Where
- Boston
- Életkor
- 16 év to 75 év
- People
- 94
- Run by
- Luminary Therapeutics
See details and how to joinNCT07729995 - 1/2. fázisTaking peopleDescartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
- Where
- Cincinnati, St Louis, Washington D.C.
- Életkor
- 12 év and over
- People
- 50
- Run by
- Cartesian Therapeutics
See details and how to joinNCT07089121 - 1. fázisTaking peoplePhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Where
- Amarillo, Austin, Baltimore, Chapel Hill, Columbus, Houston, Lake Success, New York, Orange, Philadelphia, Portland
- Életkor
- 18 év to 85 év
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00 - 1. fázisTaking peopleA Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Where
- Boston, Durham
- Életkor
- 18 év and over
- People
- 125 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00